source
- Lilly pens another deal, inking up to $5.9B oncology pact with StippleA licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.BioSpace · 10h ago↗ source
- FDA to refer to AI as ‘super intelligence’ going forwardThe US Food and Drug Administration (FDA) announced that, as of Monday, it will use the term “super intelligence” instead of “artificial intelligence” in all official correspondence, public communi…raps · 1d ago↗ source
- Regulators, industry experts look to streamline EU combination product oversightBALTIMORE – A panel of European regulators and industry representatives discussed how to streamline the regulatory process for combination products in the European Union at the AFDO/RAPS Combinatio…